Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Capecitabine in Early Stage Breast Cancer
NCT00209092Phase 2Completed
- Sponsor
- Emory University
- Start
- Aug 2006
- Primary completion
- Jul 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, capecitabine in breast cancer, sponsored by Emory University. Started Aug 2006; status: completed.
02
Drugs
docetaxelcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00209092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00209092.